Skip to main content

Sensus Healthcare, Inc. (SRTS)

New York Stock Exchange Healthcare Medical - DevicesView data quality →
42.4Fair

ValueMarkers Composite Index

Top 10%#40,213 of 44,707
Overvalued

274% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-3.65
Low Risk
Altman
9.18
Safe
DCF Value
$1
Overvalued
ROIC
-17.0%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Sensus Healthcare, Inc. (SRTS) — VMCI valuation read

SRTS screens at VMCI 42/100, a 8-point gap below the Healthcare sector median (50). For a mid-cap Sensus Healthcare, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SRTS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SRTS trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 0.6x leaves covenant headroom, which sets the rate-cycle exposure for Sensus Healthcare, Inc..

SRTS rose 1.2% over the trailing 7 days, with a -8.5% read on a 30-day basis.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

CEO: Joseph C. Sardano54 employeesUSwww.sensushealthcare.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in SRTS’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.